← Back to Search

Brain Amyloid Imaging for Alzheimer's Disease

Phase 4
Waitlist Available
Led By Val Lowe, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 30-100
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 20 years
Awards & highlights

Study Summary

This trial will use Pittsburgh Compound B positron emission imaging (PiB PET) to study the relationship between amyloid burden and clinical status over time.

Who is the study for?
This trial is for people aged 30-100 with various forms of dementia, including Alzheimer's and Lewy Body Disease, who are part of the Mayo Clinic aging or neurodegenerative studies. It excludes pregnant or breastfeeding women, those unable to lie still for scans, claustrophobic individuals, and anyone with MRI safety risks like pacemakers.Check my eligibility
What is being tested?
The study tests imaging agents (Pittsburgh Compound B, F-18 FDG, Tau) using PET scans to track amyloid plaque buildup in the brain over time and its link to changes in clinical status among aging individuals.See study design
What are the potential side effects?
As this is a diagnostic imaging study focusing on brain scanning techniques rather than medication or therapy trials, it does not list specific side effects related to treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 30 and 100 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 20 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 20 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.
Secondary outcome measures
To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.
To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.
To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.
+1 more

Side effects data

From 2016 Phase 2 trial • 89 Patients • NCT01607476
3%
Decreased vision
3%
Heart palpitations (moderate)
3%
Metallic taste
3%
Leg cramp (mild)
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cognitive Normal Elderly
Alzheimer's Disease
Cognitive Normal Young

Trial Design

1Treatment groups
Experimental Treatment
Group I: PiB PET, FDG PET, Tau PETExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
F-18 FDG
2010
Completed Phase 2
~270

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,175 Previous Clinical Trials
3,750,161 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,654 Previous Clinical Trials
27,997,280 Total Patients Enrolled
Val Lowe, M.D.Principal InvestigatorMayo Clinic
1 Previous Clinical Trials
250 Total Patients Enrolled

Media Library

Pittsburgh Compound B (C-11 PiB) Clinical Trial Eligibility Overview. Trial Name: NCT00950430 — Phase 4
Alzheimer's Disease Research Study Groups: PiB PET, FDG PET, Tau PET
Alzheimer's Disease Clinical Trial 2023: Pittsburgh Compound B (C-11 PiB) Highlights & Side Effects. Trial Name: NCT00950430 — Phase 4
Pittsburgh Compound B (C-11 PiB) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00950430 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment in this research project currently available?

"This research study is no longer seeking recruits. The original announcement was made April 1st 2008 and the last update occurred on September 30th 2022. For those looking for other studies, there are currently 798 trials recruiting patients with semantic dementia and 6 specifically related to Pittsburgh Compound B (C-11 PiB)."

Answered by AI

Is this research endeavor open to applicants below the age of fifty-five?

"This specific clinical study requires participants to be between the ages of 30 and 100. Furthermore, there are 43 trials for individuals below 18 years old, and 790 studies that focus on elderly patients aged 65 or above."

Answered by AI

What is the safety record of C-11 PiB (Pittsburgh Compound B) usage?

"Pittsburgh Compound B (C-11 PiB) has been approved as a safe treatment, so it is assigned the highest rating of 3 on our scale."

Answered by AI

Are there any existing investigations that make use of Pittsburgh Compound B (C-11 PiB)?

"Currently, 6 studies are investigating Pittsburgh Compound B (C-11 PiB), none of which have reached Phase 3. Several research centres in Jacksonville, Florida, and 7 other locations across the country are conducting these trials for C-11 PiB."

Answered by AI

How is Pittsburgh Compound B (C-11 PiB) employed to assist patients?

"Pittsburgh Compound B (C-11 PiB) has been used to treat chronic traumatic encephalopathy (CTE), Alzheimer's disease (AD), and enhance Positron Emission Tomography scans."

Answered by AI

Could I participate in this clinical trial?

"Eligibility for this trial necessitates that prospective participants have semantic dementia and are aged between 30 and 100 years old. The study is seeking to bring on board a total of 8000 patients."

Answered by AI

What is the maximum cap on participants in this clinical experiment?

"Unfortunately, this trial is not currently open for enrollment. It was initially posted on April 1st 2008 and last revised on September 30th 2022. However, if you are searching for more studies to participate in, there are 798 medical research projects actively recruiting patients with semantic dementia and 6 trials involving C-11 PiB that are still accepting participants."

Answered by AI
~82 spots leftby Jun 2024